image
Healthcare - Medical - Devices - NYSE - US
$ 17.345
-0.602 %
$ 797 M
Market Cap
36.9
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 30, 2025.

The intrinsic value of one AVNS stock under the worst case scenario is HIDDEN Compared to the current market price of 17.3 USD, Avanos Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 30, 2025.

The intrinsic value of one AVNS stock under the base case scenario is HIDDEN Compared to the current market price of 17.3 USD, Avanos Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 30, 2025.

The intrinsic value of one AVNS stock under the best case scenario is HIDDEN Compared to the current market price of 17.3 USD, Avanos Medical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
673 M REVENUE
-17.89%
4.2 M OPERATING INCOME
-94.32%
-61.8 M NET INCOME
-122.38%
32.4 M OPERATING CASH FLOW
-64.36%
21.6 M INVESTING CASH FLOW
115.95%
-94.2 M FINANCING CASH FLOW
-166.14%
170 M REVENUE
-0.76%
12 M OPERATING INCOME
-25.47%
4.3 M NET INCOME
0.00%
23 M OPERATING CASH FLOW
-17.27%
-12 M INVESTING CASH FLOW
-103.39%
-16 M FINANCING CASH FLOW
-220.00%
Balance Sheet Avanos Medical, Inc.
image
Current Assets 487 M
Cash & Short-Term Investments 87.7 M
Receivables 143 M
Other Current Assets 256 M
Non-Current Assets 1.21 B
Long-Term Investments 0
PP&E 144 M
Other Non-Current Assets 1.06 B
Current Liabilities 235 M
Accounts Payable 56.3 M
Short-Term Debt 21.4 M
Other Current Liabilities 157 M
Non-Current Liabilities 222 M
Long-Term Debt 188 M
Other Non-Current Liabilities 33.8 M
EFFICIENCY
Earnings Waterfall Avanos Medical, Inc.
image
Revenue 673 M
Cost Of Revenue 294 M
Gross Profit 380 M
Operating Expenses 376 M
Operating Income 4.2 M
Other Expenses 66 M
Net Income -61.8 M
RATIOS
56.39% GROSS MARGIN
56.39%
0.62% OPERATING MARGIN
0.62%
-9.18% NET MARGIN
-9.18%
-5.00% ROE
-5.00%
-3.65% ROA
-3.65%
0.36% ROIC
0.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avanos Medical, Inc.
image
Net Income -61.8 M
Depreciation & Amortization 46.1 M
Capital Expenditures -17.8 M
Stock-Based Compensation 15.8 M
Change in Working Capital -18 M
Others 3 M
Free Cash Flow 14.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avanos Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for AVNS of $25.8 , with forecasts ranging from a low of $20 to a high of $33 .
AVNS Lowest Price Target Wall Street Target
20 USD 15.31%
AVNS Average Price Target Wall Street Target
25.8 USD 48.94%
AVNS Highest Price Target Wall Street Target
33 USD 90.26%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Avanos Medical, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
153 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
9.92 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
10 months ago
Mar 14, 2024
Sell 72.6 K USD
Greiner Michael
SVP - Chief Financial Officer
- 3800
19.11 USD
10 months ago
Mar 14, 2024
Sell 13.7 K USD
Greiner Michael
SVP - Chief Financial Officer
- 714
19.12 USD
10 months ago
Mar 14, 2024
Sell 42.7 K USD
Greiner Michael
SVP - Chief Financial Officer
- 2231
19.13 USD
10 months ago
Mar 14, 2024
Sell 6.45 K USD
Greiner Michael
SVP - Chief Financial Officer
- 337
19.14 USD
10 months ago
Mar 14, 2024
Sell 15.5 K USD
Greiner Michael
SVP - Chief Financial Officer
- 808
19.15 USD
10 months ago
Mar 14, 2024
Sell 2.11 K USD
Greiner Michael
SVP - Chief Financial Officer
- 110
19.16 USD
10 months ago
Mar 11, 2024
Bought 9.92 K USD
Shimer Julie Ann
Director
+ 500
19.85 USD
3 years ago
Sep 15, 2021
Bought 25.3 K USD
OLEARY PATRICK J
Director
+ 800
31.67 USD
3 years ago
Sep 15, 2021
Bought 28.5 K USD
OLEARY PATRICK J
Director
+ 900
31.65 USD
3 years ago
Sep 15, 2021
Bought 27 K USD
OLEARY PATRICK J
Director
+ 853
31.62 USD
3 years ago
Sep 15, 2021
Bought 77.3 K USD
OLEARY PATRICK J
Director
+ 2447
31.61 USD
4 years ago
May 08, 2020
Bought 142 K USD
BLACKFORD GARY
Director
+ 5000
28.5 USD
4 years ago
May 08, 2020
Bought 145 K USD
BLACKFORD GARY
Director
+ 5000
29 USD
5 years ago
May 30, 2019
Bought 140 K USD
Woody Joseph Fralin
Chief Executive Officer
+ 3500
39.95 USD
6 years ago
Nov 28, 2018
Bought 152 K USD
Woody Joseph Fralin
Chief Executive Officer
+ 3500
43.35 USD
6 years ago
Nov 27, 2018
Bought 87.5 K USD
Voskuil Steven E
SVP, Chief Financial Officer
+ 2000
43.735 USD
6 years ago
Nov 19, 2018
Bought 47.5 K USD
Wesley John W
SVP, General Counsel
+ 1000
47.48 USD
9 years ago
Sep 04, 2015
Bought 311 K USD
ABERNATHY ROBERT E
Chairman and CEO
+ 10000
31.06 USD
9 years ago
Sep 01, 2015
Bought 30 K USD
Voskuil Steven E
SVP, Chief Financial Officer
+ 1000
30 USD
7. News
Avanos Medical, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference ALPHARETTA, Ga. , Jan. 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will present at the 43rd  Annual J.P. prnewswire.com - 3 weeks ago
New Strong Sell Stocks for December 11th AVNS, BATRK and ELV have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2024. zacks.com - 1 month ago
Avanos Medical, Inc. to Present at the Stifel 2024 Healthcare Conference ALPHARETTA, Ga. , Nov. 12, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in an analyst-led fireside chat at the Stifel 2024 Healthcare Conference at the Lotte New York Palace in New York on Tuesday, Nov. 19 at approximately 3:35 p.m. prnewswire.com - 2 months ago
ON-Q* Elastomeric Infusion Pump and ambIT* Disposable Electronic Infusion Pump to Receive Separate Payment Under NOPAIN Act Starting January 1, 2025 ALPHARETTA, Ga. , Nov. 11, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025. prnewswire.com - 2 months ago
Avanos Medical, Inc. to Present at the UBS Healthcare Conference 2024 ALPHARETTA, Ga. , Nov. 8, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in a fireside chat at the UBS 2024 Healthcare Conference on Tues. prnewswire.com - 2 months ago
Avanos Medical Launches New CORGRIP® SR Advancement to reduce dislodgement in feeding tube retention systems ALPHARETTA, Ga. , Nov. 5, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the launch of its newly designed CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, further expanding its comprehensive Enteral Feeding portfolio. prnewswire.com - 2 months ago
Are Investors Undervaluing Avanos Medical (AVNS) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 months ago
Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts Avanos Medical, Inc. AVNS reported third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 36 cents, up 20% year over year. The bottom line met the Zacks Consensus Estimate. zacks.com - 3 months ago
Avanos Medical Inc. (AVNS) Q3 2024 Earnings Call Transcript Avanos Medical Inc. (NYSE:AVNS ) Q3 2024 Results Conference Call October 30, 2024 9:00 AM ET Company Participants Scott Galovan - Vice President of Strategy & Corporate Development Gary Blackford - Chairman Michael Greiner - Senior VP, CFO & Chief Transformation Officer Conference Call Participants Kristen Stewart - CL King Danny Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos Third Quarter 2024 Earnings Call. [Operator Instructions] This call is being recorded on Wednesday, October 30, 2024. seekingalpha.com - 3 months ago
Avanos Medical (AVNS) Q3 Earnings Meet Estimates Avanos Medical (AVNS) came out with quarterly earnings of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago. zacks.com - 3 months ago
Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO ALPHARETTA, Ga. , Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. prnewswire.com - 3 months ago
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2024 Financial Results ALPHARETTA, Ga. , Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m. prnewswire.com - 3 months ago
8. Profile Summary

Avanos Medical, Inc. AVNS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 797 M
Dividend Yield 0.00%
Description Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Contact 5405 Windward Parkway, Alpharetta, GA, 30004 https://avanos.com
IPO Date Oct. 21, 2014
Employees 3771
Officers Ms. Michelle Scharfenberg Senior Vice President and Chief Ethics & Compliance Officer Mr. Kerr W. Holbrook Senior Vice President & Chief Commercial Officer Mr. David Crawford Vice President of FP&A and Investor Relations and Treasurer John W. Cato Vice President of Human Resources Mr. John Joseph Hurley Principal Accounting Officer & Controller Ms. Mojirade James Senior Vice President, General Counsel & Corporate Secretary Mr. Michael C. Greiner CPA Interim Chief Executive Officer, Senior Vice President & Chief Transformation Officer Mr. Scott Galovan Vice President of Strategy & Corporate Development Mr. Warren J. Machan Interim Chief Financial Officer Mr. Lee Burnes Senior Vice President of Global R&D, Clinical and Medical Affairs